Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
46.12
+0.73 (+1.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dyne Therapeutics Inc
< Previous
1
2
Next >
Dyne Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
May 25, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
May 17, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
May 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
May 02, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
March 23, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
March 20, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
March 07, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 02, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Investor Conferences in November
November 02, 2022
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
October 31, 2022
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
October 11, 2022
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform
March 17, 2022
SAN RAMON, CA / ACCESSWIRE / March 17, 2022 / Grid Dynamics Holdings, Inc. (NASDAQ:DYN) (Grid Dynamics), a leader in enterprise-level digital engineering services and solutions, today announced it has...
From
Grid Dynamics
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.